BioSpace News Archive

Illumina, Inc. announced an agreement with Israel’s Ministry of Health for a pilot program to implement the use of whole-genome sequencing in critically-ill infants suspected of having a genetic disorder in neonatal intensive care units.

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2021 financial results before the market opens on Wednesday, November 3, 2021 .

Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the third quarter ended October 2, 2021.

Ocugen, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that it has submitted an Investigational New Drug application with the U.S. Food and Drug Administration to evaluate the COVID-19 vaccine candidate, BBV152, known as COVAXIN™ outside the United States.

ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that it has acquired all of AgBiome Delta, LLC’s shares of Life Edit Therapeutics, Inc. Life Edit offers a powerful suite of gene editing technologies that have the potential for any genomic sequence of interest to be removed, added, or altered.

Merck, known as MSD outside the United States and Canada, announced Week 144 data from the Phase 2b dose-ranging study evaluating the antiretroviral activity, tolerability, and safety of islatravir in combination with doravirine compared to doravirine/lamivudine/tenofovir disoproxil fumarate in antiretroviral treatment-naïve adults with HIV-1.

Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced the completion of enrollment in the company’s ongoing Phase 2b study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy.

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter on Tuesday, November 9th, 2021.

Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced the signing of a master supply and services agreement with Otsuka Pharmaceutical Co., Ltd.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), today presented new safety, pharmacokinetic (PK) and pharmacodynamic (PD) data, including cytokines, from the Single Ascending Dose (SAD) portion of the KT-474 Phase 1 randomized, placebo-controlled healthy volunteer trial, at the 4th Annual Targeted Protein Degradation Summit.